The Seed Oil Panic: Health Crisis or Misdirected Hysteria?
In the kaleidoscopic world of modern nutrition, villains change often. Once it was saturated fat. Then it was carbs. Now, ...
Science vs. Slogan: The Growing Rift Between RFK Jr. and the Public Health Establishment
On April 15, a coalition of 17 national public health organizations, spearheaded by the American Public Health Advocacy Network (APHAN), ...
The Coming Pharma Tariffs: Decoding Trump’s High-Stakes Bet on Drug Supply Chains
Introduction: The Tariff Test Case No One Is Talking About For all the attention given to tariffs on steel, aluminum, ...
The Silence Clause: NIH Halts Grants to Top Universities Amid Veiled Directives
On a quiet Tuesday afternoon in March, a cryptic internal email circulated through the National Institutes of Health (NIH), addressed ...
Fit for Office: Trump’s Health Report Renews Debate on Presidential Transparency
The White House released a brief but definitive medical report on Sunday morning declaring that former President Donald Trump “exhibits ...
Medical Journals Under Scrutiny: DOJ’s Quiet Inquiry Into Scientific Dissent
In the wake of COVID-19 and the increasing politicization of public health, the U.S. Department of Justice has taken an ...
The Physician on Trial: A Broken System, A Profession Reborn
Bad news travels fast. But good news? That takes time. And when it comes to the federal prosecution of physicians, ...
What Google Searches Tell Us About the Future of Healthcare
If you want to understand where healthcare is going, start by asking what people are Googling. That’s the philosophy behind ...
The Search for Certainty: What Google Reveals About How We Think About Health
In the waiting rooms of America, a familiar ritual plays out every day. A patient glances at their phone, opens ...
From Burden to Breakthrough: Why 81% of Physicians Are Ready to Embrace AI
In a profession built on human connection, the growing embrace of artificial intelligence might seem counterintuitive. But when 81% of ...
Tariffs and Trade-Offs: How Trump’s China Tariff Hike Could Ripple Through U.S. Healthcare
The announcement landed like a stone in murky waters — rippling outward in waves no one could fully map. In ...
What Happens When the Match Ends? States Brace for Impact as CMS Shifts Medicaid Funding Rules
When a federal agency changes the way money flows, the effects aren’t always immediate — but they’re often profound. In ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
-
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
-
The Importance of Access Control in the Workplace
-
Detecting Hospital M&A Synergies Before They’re Announced: A Rate-Based Event Strategy
-
The ASC Rate Arbitrage: How Ambulatory Surgery Center Growth Looks in Procedure-Level Price Data
